SCHEMBL4152912

SCHEMBL4152912

O=C(Nc1cccnc1)c1ccnc2[nH]c(-c3ccc(N4CCOCC4)cc3)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
GSK3B P49841 3/20 0.52
MTOR P42345 4/20 0.49
PIK3CA P42336 2/20 0.49
PIK3CG P48736 2/20 0.49
IRAK4 Q9NWZ3 1/20 0.49
PIK3CD O00329 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
AKT1 P31749 1/20 0.46
DGAT1 O75907 1/20 0.46
ATR Q13535 1/20 0.46
MCL1 Q07820 1/20 0.46
PARP1 P09874 1/20 0.45
MAPK10 P53779 1/20 0.45
KMT2A Q03164 1/20 0.44
ABCB1 P08183 1/20 0.44
CCNE2 O96020 1/20 0.44
CCNE1 P24864 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152109 0.92 GSK3B (0.53) TP53SMN1; SMN2GSK3BIRAK4NPC1
SCHEMBL4152711 0.92 MAPK10 (0.54) TP53SMN1; SMN2NPC1RAB9ADGAT1
SCHEMBL4160814 0.90 LRRK2 (0.53) SMN1; SMN2GSK3BMTORIRAK4NPC1
SCHEMBL3945101 0.88 PARP1 (0.51) TP53SMN1; SMN2GSK3BMTORPIK3CA
SCHEMBL4157085 0.86 PDE4B (0.48) TP53SMN1; SMN2GSK3BMTORPIK3CA
SCHEMBL8237423 0.85 GSK3B (0.47) TP53SMN1; SMN2GSK3BIRAK4NPC1
SCHEMBL4148276 0.84 GSK3B (0.52) GSK3BNPC1RAB9ADGAT1PARP1
SCHEMBL4156450 0.82 GSK3B (0.74) GSK3BMCL1KMT2A
SCHEMBL4145805 0.81 GSK3B (0.55) TP53SMN1; SMN2GSK3BMTORPIK3CA
SCHEMBL4161584 0.81 RAB9A (0.51) TP53SMN1; SMN2IRAK4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 TP53 480/4885SMN1; SMN2 3695/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.